The narrative presents a cautiously optimistic view of the biotech IPO market's recovery, grounded in observable data and expert commentary. The strongest version of this argument acknowledges the tangible uptick in activity—$1.4 billion raised in February, multiple high-profile listings, and a growing pipeline of candidates—while tempering expectations with the mixed post-IPO performance and lingering macroeconomic risks. The analysis avoids hyperbolic claims, instead framing the recovery as gr...